Bordetella pertussis iron regulated proteins as potential vaccine components

Vaccine

Volumn 31, Issue 35, 2013, Pages 3543-3548

  Alvarez Hayes, Jimena ^a   Erben, Esteban ^b   Lamberti, Yanina ^a   Principi, Guido ^c   Maschi, Fabricio ^c   Ayala, Miguel ^c   Rodriguez, Maria Eugenia ^a  

^a Universidad Nacional de La Plata   (Argentina)

^b INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

^c UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

Bordetella pertussis; New antigens; Vaccine

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FERROPORTIN 1; IRON BINDING PROTEIN; IRON REGULATED PROTEIN 2; IRON REGULATED PROTEIN 3; PROTEIN AFUA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; INFECTION; INFECTION CONTROL; MOUSE; NONHUMAN; OPSONIZATION; OUTCOME ASSESSMENT; PERTUSSIS; PHAGOCYTOSIS; PRIORITY JOURNAL;

BORDETELLA PERTUSSIS; NEW ANTIGENS; VACCINE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CELLS, CULTURED; FEMALE; HUMANS; IRON REGULATORY PROTEIN 1; MICE; MICE, INBRED BALB C; NEUTROPHILS; OPSONIN PROTEINS; PERTUSSIS VACCINE; VACCINATION; WHOOPING COUGH;

EID: 84880758335     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.072     Document Type: Article

References (49)

1. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18(2):326-382.
2. Uhl M.A., Miller J.F. Autophosphorylation and phosphotransfer in the Bordetella pertussis BvgAS signal transduction cascade. Proc Natl Acad Sci USA 1994, 91(3):1163-1167.
3. Weiss A.A., Hewlett E.L., Myers G.A., Falkow S. Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect Immun 1983, 42(1):33-41.
4. Cotter P.A., Jones A.M. Phosphorelay control of virulence gene expression in Bordetella. Trends Microbiol 2003, 11(8):367-373.
5. Cotter P.A., Miller J.F. A mutation in the Bordetella bronchiseptica bvgS gene results in reduced virulence and increased resistance to starvation, and identifies a new class of Bvg-regulated antigens. Mol Microbiol 1997, 24(4):671-685.
6. Guris D., Strebel P.M., Bardenheier B., Brennan M., Tachdjian R., Finch E., et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999, 28(6):1230-1237.
7. Ntezayabo B., De Serres G., Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003, 22(1):22-27.
8. Baron S., Njamkepo E., Grimprel E., Begue P., Desenclos J.C., Drucker J., et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998, 17(5):412-418.
9. Bouchez V., Brun D., Cantinelli T., Dore G., Njamkepo E., Guiso N. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine 2009, 27(43):6034-6041.
10. Otsuka N., Han H.J., Toyoizumi-Ajisaka H., Nakamura Y., Arakawa Y., Shibayama K., et al. Prevalence and Genetic Characterization of Pertactin-Deficient Bordetella pertussis in Japan. PLoS ONE 2012, 7(2):e31985.
11. Barkoff A.M., Mertsola J., Guillot S., Guiso N., Berbers G., He Q. Appearance of Bordetella pertussis strains not expressing vaccine antigen pertactin in Finland. Clin Vaccine Immunol 2012, 19(10):1703-1704.
12. Mahan M.J., Heithoff D.M., Sinsheimer R.L., Low D.A. Assessment of bacterial pathogenesis by analysis of gene expression in the host. Annu Rev Genet 2000, 34:139-164.
13. Ratledge C., Dover L.G. Iron metabolism in pathogenic bacteria. Annu Rev Microbiol 2000, 54:881-941.
14. Neilands J.B. Siderophores: structure and function of microbial iron transport compounds. J Biol Chem 1995, 270(45):26723-26726.
15. Pradel E., Guiso N., Menozzi F.D., Locht C. Bordetella pertussis TonB, a Bvg-independent virulence determinant. Infect Immun 2000, 68(4):1919-1927.
16. Brickman T.J., Hanawa T., Anderson M.T., Suhadolc R.J., Armstrong S.K. Differential expression of Bordetella pertussis iron transport system genes during infection. Mol Microbiol 2008, 70(1):3-14.
17. Brickman T.J., Armstrong S.K. Impact of alcaligin siderophore utilization on in vivo growth of Bordetella pertussis. Infect Immun 2007, 75(11):5305-5312.
18. Brickman T.J., Vanderpool C.K., Armstrong S.K. Heme transport contributes to in vivo fitness of Bordetella pertussis during primary infection in mice. Infect Immun 2006, 74(3):1741-1744.
19. Vidakovics M.L., Paba J., Lamberti Y., Ricart C.A., de Sousa M.V., Rodriguez M.E. Profiling the Bordetella pertussis proteome during iron starvation. J Proteome Res 2007, 6(7):2518-2528.
20. Alvarez Hayes J., Erben E., Lamberti Y., Ayala M., Maschi F., Carbone C., et al. Identification of a new protective antigen of Bordetella pertussis. Vaccine 2011, 29(47):8731-8739.
21. Chen C.Y., Berish S.A., Morse S.A., Mietzner T.A. The ferric iron-binding protein of pathogenic Neisseria spp. functions as a periplasmic transport protein in iron acquisition from human transferrin. Mol Microbiol 1993, 10(2):311-318.
22. Khan A.G., Shouldice S.R., Kirby S.D., Yu R.H., Tari L.W., Schryvers A.B. High-affinity binding by the periplasmic iron-binding protein from Haemophilus influenzae is required for acquiring iron from transferrin. Biochem J 2007, 404(2):217-225.
23. Tom-Yew S.A., Cui D.T., Bekker E.G., Murphy M.E. Anion-independent iron coordination by the Campylobacter jejuni ferric binding protein. J Biol Chem 2005, 280(10):9283-9290.
24. Gomez J.A., Criado M.T., Ferreiros C.M. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants. FEMS Immunol Med Microbiol 1998, 20(1):79-86.
25. Brickman T.J., Cummings C.A., Liew S.Y., Relman D.A., Armstrong S.K. Transcriptional profiling of the iron starvation response in Bordetella pertussis provides new insights into siderophore utilization and virulence gene expression. J Bacteriol 2011, 193(18):4798-4812.
26. Relman D.A., Domenighini M., Tuomanen E., Rappuoli R., Falkow S. Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. Proc Natl Acad Sci USA 1989, 86(8):2637-2641.
27. Rodriguez M.E., Hellwig S.M., Hozbor D.F., Leusen J., van der Pol W.L., van de Winkel J.G. Fc receptor-mediated immunity against Bordetella pertussis. J Immunol 2001, 167(11):6545-6551.
28. Kirimanjeswara G.S., Agosto L.M., Kennett M.J., Bjornstad O.N., Harvill E.T. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest 2005, 115(12):3594-3601.
29. Gorgojo J., Lamberti Y., Valdez H., Harvill E.T., Rodriguez M.E. Bordetella parapertussis survives the innate interaction with human neutrophils by impairing bactericidal trafficking inside the cell through a lipid raft-dependent mechanism mediated by the lipopolysaccharide O antigen. Infect Immun 2012, 80(12):4309-4316.
30. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334(6179):255-258.
31. Sato Y., Sato H. Development of acellular pertussis vaccines. Biologicals 1999, 27(2):61-69.
32. Wood N., McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev 2008, 9(3):201-211.
33. Das P. Whooping cough makes global comeback. Lancet Infect Dis 2002, 2(6):322.
34. Kallonen T., He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines 2009, 8(7):863-875.
35. Mooi F.R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 2009, 10(1):36-49.
36. Sukumar N., Love C.F., Conover M.S., Kock N.D., Dubey P., Deora R. Active and passive immunizations with Bordetella colonization factor A protect mice against respiratory challenge with Bordetella bronchiseptica. Infect Immun 2009, 77(2):885-895.
37. Marr N., Oliver D.C., Laurent V., Poolman J., Denoel P., Fernandez R.C. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 2008, 26(34):4306-4311.
38. Sukumar N., Sloan G.P., Conover M.S., Love C.F., Mattoo S., Kock N.D., et al. Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines. Infect Immun 2010, 78(5):2008-2016.
39. Mielcarek N., Debrie A.S., Raze D., Quatannens J., Engle J., Goldman W.E., et al. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine 2006, 24(Suppl. 2). S2-54-5.
40. Mills K.H., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993, 61(2):399-410.
41. Gomez J.A., Agra C., Ferron L., Powell N., Pintor M., Criado M.T., et al. Antigenicity, cross-reactivity and surface exposure of the Neisseria meningitidis 37kDa protein (Fbp). Vaccine 1996, 14(14):1340-1346.
42. Shafer W.M., Morse S.A. Cleavage of the protein III and major iron-regulated protein of Neisseria gonorrhoeae by lysosomal cathepsin G. J Gen Microbiol 1987, 133(1):155-162.
43. Mietzner T.A., Luginbuhl G.H., Sandstrom E., Morse S.A. Identification of an iron-regulated 37,000-dalton protein in the cell envelope of Neisseria gonorrhoeae. Infect Immun 1984, 45(2):410-416.
44. Berish S.A., Chen C.Y., Mietzner T.A., Morse S.A. Expression of a functional neisserial fbp gene in Escherichia coli. Mol Microbiol 1992, 6(18):2607-2615.
45. Lamberti Y., Perez Vidakovics M.L., van der Pol L.W., Rodriguez M.E. Cholesterol-rich domains are involved in Bordetella pertussis phagocytosis and intracellular survival in neutrophils. Microb Pathog 2008, 44(6):501-511.
46. Lamberti Y.A., Hayes J.A., Perez Vidakovics M.L., Harvill E.T., Rodriguez M.E. Intracellular trafficking of Bordetella pertussis in human macrophages. Infect Immun 2010, 78(3):907-913.
47. Cassiday P., Sanden G., Heuvelman K., Mooi F., Bisgard K.M., Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 2000, 182(5):1402-1408.
48. Hellwig S.M., Rodriguez M.E., Berbers G.A., van de Winkel J.G., Mooi F.R. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 2003, 188(5):738-742.
49. Vergara-Irigaray N., Chavarri-Martinez A., Rodriguez-Cuesta J., Miller J.F., Cotter P.A., Martinez de Tejada G. Evaluation of the role of the Bvg intermediate phase in Bordetella pertussis during experimental respiratory infection. Infect Immun 2005, 73(2):748-760.